| Kari R Ryan, CRNA | |
|
2220 Canterbury Dr, Hays, KS 67601-2370 | |
| (785) 628-8300 | |
| (785) 623-4634 |
| Full Name | Kari R Ryan |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 19 Years |
| Location | 2220 Canterbury Dr, Hays, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558356154 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 55461 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hays Medical Center | Hays, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hays Medical Center Inc | 1557279676 | 158 |
News Archive
A new study has uncovered low rates of referral for palliative care in US patients with end-stage liver disease, although rates have been slowly increasing over time.
To date, the underlying causes of inflammation in obesity and type 2 diabetes mellitus have been poorly understood, which has hampered efforts to develop treatments to prevent complications from a disease that is the third leading cause of death in the United States.
Scientists at Karolinska Institutet in Sweden describe in a new study how so-called DNA origami can enhance the effect of certain cytostatics used in the treatment of cancer. With the aid of modern nanotechnology, scientists can target drugs direct to the tumour while leaving surrounding healthy tissue untouched.
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
› Verified 4 days ago
| Entity Name | Hays Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770618258 PECOS PAC ID: 1557279676 Enrollment ID: O20040224000687 |
News Archive
A new study has uncovered low rates of referral for palliative care in US patients with end-stage liver disease, although rates have been slowly increasing over time.
To date, the underlying causes of inflammation in obesity and type 2 diabetes mellitus have been poorly understood, which has hampered efforts to develop treatments to prevent complications from a disease that is the third leading cause of death in the United States.
Scientists at Karolinska Institutet in Sweden describe in a new study how so-called DNA origami can enhance the effect of certain cytostatics used in the treatment of cancer. With the aid of modern nanotechnology, scientists can target drugs direct to the tumour while leaving surrounding healthy tissue untouched.
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kari R Ryan, CRNA 2220 Canterbury Dr, Hays, KS 67601-2370 Ph: (785) 623-5096 | Kari R Ryan, CRNA 2220 Canterbury Dr, Hays, KS 67601-2370 Ph: (785) 628-8300 |
News Archive
A new study has uncovered low rates of referral for palliative care in US patients with end-stage liver disease, although rates have been slowly increasing over time.
To date, the underlying causes of inflammation in obesity and type 2 diabetes mellitus have been poorly understood, which has hampered efforts to develop treatments to prevent complications from a disease that is the third leading cause of death in the United States.
Scientists at Karolinska Institutet in Sweden describe in a new study how so-called DNA origami can enhance the effect of certain cytostatics used in the treatment of cancer. With the aid of modern nanotechnology, scientists can target drugs direct to the tumour while leaving surrounding healthy tissue untouched.
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
› Verified 4 days ago
Rick Abbott, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 3701 Fairway Dr, Hays, KS 67601 Phone: 785-769-4416 | |
Krista Renee Dechant, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2220 Canterbury Dr, Hays, KS 67601 Phone: 785-628-8300 | |
Mrs. Taylor David, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2220 Canterbury Dr, Hays, KS 67601 Phone: 855-429-7633 | |
Jana Bieberle, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2220 Canterbury Dr, Hays, KS 67601 Phone: 855-429-7633 | |
Ronald E Boyson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1904 E 29th St, Hays, KS 67601 Phone: 785-650-0600 | |
James Gordon Manning Iii, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1904 E 29th Street, Hays, KS 67601 Phone: 785-650-0600 Fax: 785-650-0143 |